NME9

Across TCGA pan-cancer cohorts, NME9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NME9 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher NME9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NME9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

UCEC, LSCC, and LUAD are the cancer types where NME9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.863	.006	8	view →
LSCC	DFS	Median	III,IV	1.000	0.795	.036	2	view →
LUAD	OS	Median	II,III,IV	1.000	0.910	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NME9–UCEC (DFS)

Open the UCEC breakdown →